TY  - GEN
AU  - Goodkin,D E
AU  - Shulman,M
AU  - Winkelhake,J
AU  - Waubant,E
AU  - Andersson,P
AU  - Stewart,T
AU  - Nelson,S
AU  - Fischbein,N
AU  - Coyle,P K
AU  - Frohman,E
AU  - Jacobs,L
AU  - Holcenberg,J
AU  - Lee,M
AU  - Mocci,S
TI  - A phase I trial of solubilized DR2:MBP84-102 (AG284) in multiple sclerosis
SN  - 0028-3878
PY  - 2000///0504
KW  - Adult
KW  - Autoantibodies
KW  - blood
KW  - Brain
KW  - pathology
KW  - Dose-Response Relationship, Immunologic
KW  - Double-Blind Method
KW  - Female
KW  - HLA Antigens
KW  - immunology
KW  - HLA-DR2 Antigen
KW  - Humans
KW  - Immunotherapy
KW  - Interferon-gamma
KW  - metabolism
KW  - Magnetic Resonance Imaging
KW  - Male
KW  - Middle Aged
KW  - Multiple Sclerosis, Chronic Progressive
KW  - Myelin Basic Protein
KW  - adverse effects
KW  - Myelin Proteins
KW  - Myelin-Associated Glycoprotein
KW  - Myelin-Oligodendrocyte Glycoprotein
KW  - Peptide Fragments
KW  - T-Lymphocytes
KW  - Treatment Outcome
KW  - Vaccines, Conjugate
N1  - Publication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1212/wnl.54.7.1414
ER  -